How COP 27 is Bringing Some Major Updates to the Business World

 

Cameron Balch, Director, Impact Cooperative gives a report on the key issues this year and how COP 27 is bringing some major updates to the business world.

Cameron’s Thoughts: 

The key issues this year are finance between governments, mainly industrial countries, and developing countries attempting to cope with climate change, to a lesser extent. There’s also a concern about methane, which is another greenhouse gas in addition to carbon, which is extremely critical based on how potent it is.

But what I really want to talk to you today is about how COP 27 is bringing some updates to the business world and that really centers around ESG. To learn more about this, the International Sustainability Standards Board is a worthwhile organization to check out. They’ve been working since last year’s COP 26, which took place in Glasgow.

They’ve been working to unify the approach to ESG worldwide. There have been a lot of competing standards and frameworks out there that different companies and really different government organizations have been lobbying for and following their lead. ISSB is bringing all of those under one roof. They’ve actually just announced some big kind of decisions that they’ve made moving forward with what they’re publishing next year. This is a single unified ESG standard that the whole world can follow.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More